A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome

This study aimed to evaluate the efficacy and safety of Ganoderma lucidum for the treatment of hyperglycaemia and other cardiovascular risk components of metabolic syndrome using a prospective, double-blind, randomised, placebo-controlled trial. Eighty-four participants with type 2 diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autores principales: Klupp, Nerida L., Kiat, Hosen, Bensoussan, Alan, Steiner, Genevieve Z., Chang, Dennis H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980683/
https://www.ncbi.nlm.nih.gov/pubmed/27511742
http://dx.doi.org/10.1038/srep29540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980683/
https://www.ncbi.nlm.nih.gov/pubmed/27511742
http://dx.doi.org/10.1038/srep29540

Ejemplares similares